The main ongoing studies: REDEFINE 1 , Phase 3 obesity without T2D (results 20242025, preliminarily 25.3 %) REDEFINE 2 , Phase 3 obesity + T2D REDEFINE 3 , Phase 3 cardiovascular outcome trial (n~7000) Stand-alone clinical development of Cagrilintide is limited , Novo Nordisk is primarily investing in the CagriSema combination
10%), hypoesthesia (6% to 8% vs
References Jackson DA, Symons RH, Berg P: Biochemical method for inserting new genetic information into DNA of simian virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli
Warnings: Allergic Reactions: Inform your healthcare provider about any known allergies, particularly towards hCG or any other components of the formulation
Waldchen, S., Lehmann, J., Klein, T., van de Linde, S & Sauer, M Light-induced cell damage in live-cell super-resolution microscopy